GlassScriptPhysician profile
Thomas C Morell
NPI 1285633156
$2,299.14
in general payments reported to CMS, 2019-2025
13 companies · $425 in 2025
The $425 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.51 · 2021: $615 · 2022: $253 · 2023: $488 · 2024: $470 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,068.94 | 2021-2025 | |
| Lilly USA, LLC | $313.85 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Boston Scientific Corporation | $225.22 | 2024 | |
| Vertos Medical, INC. | $144.22 | 2023 | Mild Device Kit |
| Spinal Simplicity, LLC | $140.33 | 2025 | Ha Minuteman G3-R |
| Alexion Pharmaceuticals, INC. | $123.73 | 2021 | |
| Pfizer INC. | $84.38 | 2023-2025 | |
| Spinefrontier, INC. | $72.64 | 2025 | Nanofuse, Facetfuse, Inspan |
| C2n Diagnostics, LLC | $31.77 | 2025 | Precivityad2 |
| Acorda Therapeutics, INC | $25.53 | 2019 | |
| Acadia Pharmaceuticals INC | $24.81 | 2024 | Nuplazid |
| Amgen INC. | $21.98 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $21.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Morell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.